Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 15/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2586606 | 1.00 | RAPGEF4 (0.48) | RAPGEF4NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL12915426 | 1.00 | RAPGEF4 (0.48) | RAPGEF4NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL3286343 | 0.77 | MEN1 (0.48) | RAPGEF4NPC1MAPTRAB9AALDH1A1 | |
| SCHEMBL3286340 | 0.77 | MEN1 (0.48) | RAPGEF4NPC1MAPTRAB9AALDH1A1 | |
| SCHEMBL1755254 | 0.74 | RAPGEF4 (0.50) | RAPGEF4NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL27621238 | 0.69 | F2 (0.38) | RAPGEF4MAPTALDH1A1 | |
| SCHEMBL3933025 | 0.67 | MEN1 (0.68) | RAPGEF4NPC1MAPTRAB9AALDH1A1 | |
| SCHEMBL1405485 | 0.67 | MEN1 (0.68) | RAPGEF4NPC1MAPTRAB9AALDH1A1 | |
| SCHEMBL502929 | 0.66 | RAPGEF4 (1.00) | RAPGEF4 | |
| SCHEMBL502928 | 0.66 | RAPGEF4 (0.43) | RAPGEF4MAPTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9403781-B2 | Crystalline 1H-1,2,3-triazol-5-ylidenes | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-08-02 | — | — | US | disclosed |
| US-20130197178-A1 | CRYSTALLINE 1H-1,2,3-TRIAZOL-5-YLIDENES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-08-01 | — | — | US | disclosed |
| WO-2011139704-A2 | CRYSTALLINE 1H-1,2,3-TRIAZOL-5-YLIDENES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20060094591-A1 | Polymerisation catalysts | INNOVENE EUROPE LTD. (GB) | 2006-05-04 | — | — | US | disclosed |
| EP-1583778-A2 | POLYMERISATION CATALYSTS WITH TRIAZENIDO LIGANDS | Innovene Europe Limited (GB) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004063233-A2 | POLYMERISATION CATALYSTS WITH TRIAZENIDO LIGANDS | INNOVENE EUROPE LIMITED (GB) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094591-A1 | Polymerisation catalysts | NOD2, TELO2, MUS81 | RAPGEF4 3861/4885NPC1 3789/4885MAPT 3440/4885 |
| US-20130197178-A1 | CRYSTALLINE 1H-1,2,3-TRIAZOL-5-YLIDENES | TCP1, CCT3, CCT2 | RAPGEF4 3048/4885NPC1 987/4885MAPT 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.